Twenty articles that critical care clinicians should read about COVID-19

Tsang, Jennifer; Binnie, Alexandra; Fowler, Robert

doi:10.1007/s00134-020-06329-3

Cited by 12 publications

(13 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Histologic analysis of pulmonary vessels in patients with Covid-19 showed widespread thrombosis with microangiopathy [24]. These observations indicated pulmonary vascular disease in patients with Covid-19 ARDS [25]. [25].…”

Section: Discussionmentioning

confidence: 76%

Randomized Controlled Trial of DDS for Covid-19 ARDS

Lee

Kanwar²,

Lee³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Clinicians considered DDS administration to treat SARS-CoV-2 inflammasome. DDS is helpful in the molecular regulation of Nod-like receptor family pyrin domain-containing 3 (NLRP3).Objective To study the targeting of NLRP3 itself or up-/downstream factors of the NLRP3 inflammasome by DDS must be responsible for its observed preventive effects, functioning as a competitor.Methods This is a randomized controlled trial (RCT). We set out to use objective criteria of improvement. We treated the patients with standard Covid-19 acute respiratory distress syndrome (ARDS) treatment with DDS. The RCT results were analyzed.Results ARDS progression was blocked in 17 of 19 total patients at the first period. The 44 subjects were analyzed during the second period. It is significant at the ARDS onset stage. The mortality of ARDS-onset patients was 0% with DDS and 40% without DDS among the total of 65 cases. The t-value of RCT is -1.5, and the p-value is .075475. The result is significant at p < 0.10. ARDS onset with DDS prescribed group survived more 90% than ARDS onset without DDS group. The chi-square is 5.8108. The p-value is .015928. (Significant at p < .05) (RR 0.15, OR 0.09)Conclusion There was a significant difference in DDS treatment results in the ARDS-onset group. We confirmed that DDS clinically treated the onset of ARDS by targeting SARS-CoV-2-activated inflammasomes. Like chemically reacting substances, inflammasome and DDS compete, proving that it is effective in early ARDS.ClinicalTrials.gov Identifier: NCT04918914

show abstract

Section: Discussionmentioning

confidence: 76%

Randomized Controlled Trial of DDS for Covid-19 ARDS

Lee

Kanwar²,

Lee³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Histologic analysis of pulmonary vessels in patients with COVID-19 showed widespread thrombosis with microangiopathy 19 . These observations indicated pulmonary vascular disease in patients with COVID-19 ARDS 20 or it was easy to judge the result than the process.…”

Section: Discussionmentioning

confidence: 96%

“…Transient bulbar palsy through medulla oblongata may be the origin of ARDS in COVID-19 Extrapulmonary manifestations have been reported, including neurologic complications, such as stroke and encephalopathy; anosmia; cardiac complications, such as acute coronary syndrome, myocarditis, arrhythmia, and Takotsubo cardiomyopathy; renal complications, such as acute kidney injury; hepatic complications, such as transaminitis; and gastrointestinal complications, such as diarrhoea, nausea, vomiting, and anorexia 20 . With the data on these diverse complications, the relationship of the virus, its direct cytotoxic effects, its effects on the renin-angiotensin-aldosterone systems, its impact on the endothelium, and the various manifestations of COVID-19 disease was explored 23 .…”

Section: Discussionmentioning

confidence: 99%

Specific Treatment exists for SARS-CoV-2 ARDS

Lee¹,

Kanwar²,

Balentine³

et al. 2020

Preprint

View full text Add to dashboard Cite

The clinician should consider Covid-19 patients increasing oxygen requirement from 6l/min to as high as 100% with high flow nasal cannula: dapsone administration. A Covid-19 committee at Hunt Regional Medical Center reviewed the first-period dapsone as an off-label medication. The hospital revalidated its effectiveness and reported furthermore, 44 (22/22) patients with ARDS at second period. ARDS onset was treated with dapsone: Decreased FIO2 in 7 patients and no worse in 1 patient. ARDS aggravated was treated: Decreased FIO2 in 6 patients and no worse in 3 patients. ARDS severe was no response in 2 patients. There are eight deaths in the twenty-onset group not treated with dapsone, but no death in the seventeen-onset group treated with dapsone at total period. There was a significant difference in ARDS treatment that results in the onset group. We clinically diagnosed a transient bulbar palsy associated with SARS-CoV-2 infection in ARDS onset group. We confirmed that dapsone treated the ARDS Onset by SARS-CoV-2 inflammasome clinically.

show abstract

“…Mortality at the ARDS-onset stage from Hunt Regional hospital in Greenville, TX These observations indicated pulmonary vascular disease in patients with COVID-19 ARDS(20).By studying moderately and severely ill COVID-19 patients, we found active NLRP3 in peripheral blood mononuclear cells and postmortem patient tissue. In ammasome-derived products, such as active caspase-1 and IL-18, were observed in the sera, as well as interleukin-6 (IL-6) and LDH, markers of COVID-19 severity.…”

mentioning

confidence: 78%

“…The mortality rate was 0%, because all studied patients were survived at onset stage in the dapsone group. (Table 5) (20). With the data on these diverse complications, the relationship of the virus, its direct cytotoxic effects, its effects on the renin-angiotensin-aldosterone systems, its impact on the endothelium, and the various manifestations of COVID-19 disease was explored (23).…”

Section: Mortality Of the Ards-onset Stagementioning

confidence: 99%

The Method and Results of a Treatment Targeting SARS-CoV-2-Activated Inflammasomes

Kanwar¹,

Khattak²,

Lee³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Clinicians in critical care medicine considered dapsone administration to treat SARS-CoV-2 inflammasome. Dapsone is useful in the molecular regulation of Nod-like receptor family pyrin domain-containing 3 (NLRP3). Objective To study the targeting of NLRP3 itself or up-/downstream factors of the NLRP3 inflammasome by dapsone must be responsible for its observed preventive effects, functioning as a competitor. Methods This is case series with or without intervention; a cross-sectional study. We set out to use objective criteria of improvement, such as A. a reduction in the FIO2 requirement and B. a decrease in the progression of hypoxia. We treated the patients with standard COVID-19 ARDS treatment with dapsone 100 mg to target NLRP3 inflammasomes. Results The 22 cases were treated with standard COVID-19 therapy with dapsone (trial group), and the 22 cases were the control group. The comparison was made assuming that only decreased FIO2 was influential in the trial and control groups, which applied to only the ARDS onset stage. The chi-square statistic is 5.1836. The p-value is .02280. Fisher’s exact test statistic value is 0.0433. (The result is significant at p < .05) Furthermore, the ARDS-onset mortality rates were 0% (with dapsone) and 40% (without dapsone). Conclusion There was a significant difference in dapsone treatment results in the ARDS-onset group. We confirmed that dapsone clinically treated the onset of ARDS by targeting SARS-CoV-2-activated inflammasomes. Like chemically reacting substances, inflammasome and dapsone are competing, proving that it is only effective in treating early ARDS.

show abstract

Twenty articles that critical care clinicians should read about COVID-19

Cited by 12 publications

References 20 publications

Randomized Controlled Trial of DDS for Covid-19 ARDS

Randomized Controlled Trial of DDS for Covid-19 ARDS

Specific Treatment exists for SARS-CoV-2 ARDS

The Method and Results of a Treatment Targeting SARS-CoV-2-Activated Inflammasomes

Contact Info

Product

Resources

About